Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Datatrak, Specialty Biotech enter multi-year deal
The vaccine company will utilize the Datatrak one unified software suite to conduct a series of trials. Datatrak CEO Laurence P Birch said the input of the specialty
The vaccine company will utilize the Datatrak one unified software suite to conduct a series of trials. Datatrak CEO Laurence P Birch said the input of the specialty
Under the deal, health research discoveries made at TODAI will be advanced towards commercialization via CDRD’s drug development infrastructure, professional project management, and scientific and business expertise. TODAI
The Ventana H. pylori antibody is used in the detection of Helicobacter pylori, a bacterium which causes chronic gastritis, ulcers and stomach cancer. The antibody helps in accurate
The patent includes both structure and method claims for inducing neurogenesis and the growth of new neurons, both in-vitro and in-vivo. Neuralstem announces Notice of Allowance for two
The data base will help hospitals improve their their cash flow and maintain better outcomes as they face shrinking reimbursements and escalating costs. The new VHA PriceLYNX 2.5
The technology is said to cater to the growing needs of retail pharmacies to proactively communicate with their customers by each customer’s preferred technology method, including phone call,
Antares’ Vibex platform includes Vibex MTX, an auto-injector which is in development and enables rheumatoid arthritis patients to comfortably and safely self-inject methotrexate at home. Vibex utilizes a
Roche said the newly developed analyzers will be marketed under Roche’s cobas brand and will include three platforms which will address a range of customer needs, from low-volume
Mymetics has provided license of its intra-nasal flu vaccine, under which Solvay has developed the vaccine until 2008 and also completed phase I trial. The results demonstrated that
The collaboration was made to develop two oncology targets involved in protein-protein interactions using Vernalis’ proprietary drug discovery platform. The research milestone allows the collaboration to be expanded